Doubt cast on MS cannabis treatment

 

There is no strong evidence to back the use of cannabis extract in the treatment of multiple sclerosis (MS), it was claimed.

A review of evidence on the first licensed preparation, Sativex, said there were "limitations" which made it difficult to identify the place of the product in clinical practice.

However the makers of the drug said they believed the comments gave a misleading view and that the review writers appeared to have misunderstood important elements of trials.

Sativex, in the form of a mouth spray, contains the principal extracts - dronabinol and cannabidiol - found in the leaf and flower of the cannabis plant, and is the first cannabinoid preparation to be licensed for use in the treatment of muscle spasms in MS.

The review, in the December issue of Drug and Therapeutics Bulletin (DTB), published by BMJ Journals, says MS is estimated to affect around 60,000 people in England and Wales, and around one in every 1,000 people will develop the condition in the UK.

An increase in muscle tone, or spasticity, is a common symptom of the condition, causing involuntary spasms, immobility, disturbed sleep, and pain.

Complex combinations of drugs are sometimes needed to manage spasticity, but they do not work that well and have a range of unpleasant side-effects, the DTB says.

Sativex is intended for use as a second-line treatment in patients in whom these other options have failed. But the review said the trial data on which the success of Sativex is based are limited.

Overall, the trials, on which the drug's approval was based, did show a small difference in the numbers of patients in whom symptoms abated compared with those taking a dummy (placebo) preparation, it said.

But in many of these studies, Sativex was used for relatively short periods - from six weeks to four months. And none included an active ingredient with which the effects of Sativex could be compared.

Two of the trials included doses that exceeded the 12 daily sprays for which the preparation is licensed, it said, and one trial did not have sufficient numbers of participants to validate the results.

A third trial, which was properly designed, and did have sufficient numbers of participants, did not find any significant difference in symptom relief between those who took Sativex and those who did not, it said.

The preparation is also expensive, it added, and costs around 10 times as much as other drugs used for the secondary treatment of MS muscle spasms.

The review says the strength of the evidence is insufficient to warrant its routine use. "We believe that such limitations make it difficult to identify the place of this product in clinical practice," it concludes.

GW Pharmaceuticals, the drug's maker, said: "We are disappointed with the conclusions drawn and strongly believe these comments give a misleading view of the drug."

A spokesman said the drug had been licensed in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA) in 2010.

Dr Stephen Wright, the company's research and development director, said: "The writers appear to have misunderstood important elements of the design of Sativex clinical trials and provide a flawed assessment of Sativex data.

"Furthermore, the article contradicts the opinion of 22 separate national authorities in Europe and around the world that have granted approval for Sativex and recognise the important benefits it provides to MS patients with spasticity."

The company said the review "fails to focus on clinical trials data which form the basis for Sativex' approval and which guide its use in clinical practice."

A spokesman said: "The key Phase III data on Sativex is robust and compelling, showed highly statistically significant results for the primary and all key secondary endpoints, and is entirely consistent with the dosing recommended in the product label."

He said the DTB "significantly overstates the price of daily Sativex treatment", adding: "Follow-up of all patients prescribed Sativex in the UK, covering more than 12,000 patient years, shows that the average daily dose in long-term clinical use is four sprays per day, a daily cost of £5.50. This is half the cost assumed by the DTB."

Ed Holloway, head of care and services research at the MS Society, said: "The MHRA has already looked at the evidence surrounding Sativex and has decided it is a safe and effective treatment for spasticity - otherwise it would not have been licensed.

"The MS Society believes the MHRA is the right organisation to be making that decision and this latest paper does not provide any new evidence; it simply looks at the same evidence the MHRA has already reviewed via a rigorous process.

"As such, we do not believe this work should call into question the MHRA's decision. Sativex works for some people and we want everyone with MS to have all possible treatment options available to them to combat the symptoms of the condition."

PA

PROMOTED VIDEO
Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Tradewind Recruitment: English Teacher

    Negotiable: Tradewind Recruitment: My client is an excellent, large partially ...

    Tradewind Recruitment: Science Teacher

    £90 - £140 per day: Tradewind Recruitment: I am currently working in partnersh...

    Tradewind Recruitment: Year 3 Primary Teacher

    £100 - £150 per day: Tradewind Recruitment: Year 3 Teacher Birmingham Jan 2015...

    Ashdown Group: Lead Web Developer (ASP.NET, C#) - City of London

    £45000 - £50000 per annum + Excellent benefits: Ashdown Group: Lead Web Develo...

    Day In a Page

    Isis hostage crisis: The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power

    Isis hostage crisis

    The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power, says Robert Fisk
    Missing salvage expert who found $50m of sunken treasure before disappearing, tracked down at last

    The runaway buccaneers and the ship full of gold

    Salvage expert Tommy Thompson found sunken treasure worth millions. Then he vanished... until now
    Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

    Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

    Maverick artist Grayson Perry backs our campaign
    Assisted Dying Bill: I want to be able to decide about my own death - I want to have control of my life

    Assisted Dying Bill: 'I want control of my life'

    This week the Assisted Dying Bill is debated in the Lords. Virginia Ironside, who has already made plans for her own self-deliverance, argues that it's time we allowed people a humane, compassionate death
    Move over, kale - cabbage is the new rising star

    Cabbage is king again

    Sophie Morris banishes thoughts of soggy school dinners and turns over a new leaf
    11 best winter skin treats

    Give your moisturiser a helping hand: 11 best winter skin treats

    Get an extra boost of nourishment from one of these hard-working products
    Paul Scholes column: The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him

    Paul Scholes column

    The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him
    Frank Warren column: No cigar, but pots of money: here come the Cubans

    Frank Warren's Ringside

    No cigar, but pots of money: here come the Cubans
    Isis hostage crisis: Militant group stands strong as its numerous enemies fail to find a common plan to defeat it

    Isis stands strong as its numerous enemies fail to find a common plan to defeat it

    The jihadis are being squeezed militarily and economically, but there is no sign of an implosion, says Patrick Cockburn
    Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action

    Virtual reality: Seeing is believing

    Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
    Homeless Veterans appeal: MP says Coalition ‘not doing enough’

    Homeless Veterans appeal

    MP says Coalition ‘not doing enough’ to help
    Larry David, Steve Coogan and other comedians share stories of depression in new documentary

    Comedians share stories of depression

    The director of the new documentary, Kevin Pollak, tells Jessica Barrett how he got them to talk
    Has The Archers lost the plot with it's spicy storylines?

    Has The Archers lost the plot?

    A growing number of listeners are voicing their discontent over the rural soap's spicy storylines; so loudly that even the BBC's director-general seems worried, says Simon Kelner
    English Heritage adds 14 post-war office buildings to its protected lists

    14 office buildings added to protected lists

    Christopher Beanland explores the underrated appeal of these palaces of pen-pushing
    Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

    Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

    Scientists unearthed the cranial fragments from Manot Cave in West Galilee